僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Ixekizumab （LY2439821） is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A （KD<3 pM）. Ixekizumab directly blocks IL-17A binding to IL-17RA （IL-17A receptor） but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis